Estudio de extensión abierto del fármaco oral CEP-701 en pacientes con enfermedades malignas hematológicas y no hematológicas que han participado en un estudio clínico del CEP-701 To assess the safety and tolerability of long term administration of CEP 701 in patients with advanced malignancy.

• Country None
• organs None
• Specialty None

The purpose of this study is to look at the safety, effectiveness, and tolerability of armodafinil when used for 6 months with mood stabilizers in subjects with major depression associated with bipolar I disorder The primary objective of this study is to evaluate the safety and tolerability of long-term (6 months) armodafinil treatment as adjunctive therapy to mood-stabilizing medications in adults with bipola...

• Country None
• organs None
• Specialty None

An 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder The primary objective of the study is to determine if armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy for adults who are experiencing a...

• Country None
• organs None
• Specialty None

A 12-week, randomized, double-blind, placebo-controlled, parallel-group. fixed-dosage study to evaluate the efficacy and safety of armodafinil (50, 150, and 250 mg/day) as treatment for patients with excessive sleepiness associated with mild or moderate closed traumatic brain injury The primary objective of the sudy is to determine whether armodafinil treatment is more effective than placebo treatment in patients with excessive sleepiness associated with mild or moderate closed t...

• Country None
• organs None
• Specialty None

Estudio abierto para determinar la dosis máxima tolerada y evaluar la eficacia y seguridad de CEP-18770 en pacientes con mieloma múltiple recidivante y resistente al tratamiento más reciente el objetivo principal de la parte 1 del estudio consiste en determinar la dosis máxima tolerada (DMT) de CEP-18770 administrado por vía intravenosa los días 1, 8 y 15 de un ciclo de 28 días en pacient...

• Country None
• organs None
• Specialty None

Estudio abierto de 12 meses para la evaluación de la seguridad, la tolerabilidad y la eficacia de armodafinil (150 mg/día y 250 mg/día) como tratamiento para pacientes con somnolencia excesiva asociada a trauma cráneo-cerebral no penetrante leve o moderado- A 12-Month, open-label Study to evaluate the Safety, Tolerability, and Efficacy of Armodafinil (150 and 250 mg/day) as Treatment for Patients with excessive Sleepiness associated with mild or moderte closed Traumatic Brain Injury el objetivo primario de este estudio es evaluar la seguridad y tolerabilidad del tratamiento de armodafinil a largo plazo (12 meses) en pacientes con somnolencia excesiva asociada a trauma cráneo-cere...

• Country None
• organs None
• Specialty None

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder The primary objective of the study is to determine whether armodafinil treatment, at dosages of 150 and 200 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers f...

• Country None
• organs None
• Specialty None

Estudio aleatorizado, doble ciego, con grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de una dosis de 200 µg de CEP-33457 en pacientes con lupus eritematoso sistémico. A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus El objetivo principal de este estudio es evaluar la eficacia de una dosis de 200 µg de CEP-33457 en comparación con placebo en pacientes con lupus eritematoso sistémico (LES) activo, en función de la ...

• Country None
• organs None
• Specialty None

A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations The primary objective is to determine whether CEP 701 treatment given in sequence with induction chemotherapy increases the proportion of patients with relapsed acute myeloid leukemia (AML) who achiev...

• Country None
• organs None
• Specialty None

A clinical study to evaluate the tolerability of repeated doses of CEP-33457 administered in patients with a chronic autoimmune disease (Lupus) The primary objective of the study is to evaluate the long term safety and tolerability of repeated administration of subcutaneous (sc) CEP 33457 every 4 weeks over 72 weeks in patients with systemic ...

• Country None
• organs None
• Specialty None